Affiliation:
1. Kazan State Medical University
Abstract
Aim: catamnestic analysis of the effectiveness of antiviral therapy for chronic hepatitis C in combination with HIV infection.Materials and methods. A retrospective study included 145 patients with combined HCV/HIV infection for 8±0,43 years.Results. 55% of patients received antiviral therapy for chronic hepatitis with pegylated interferons and ribavirin. The frequency of achieving a stable virological response is 73%. Persistent virological response with favorable Il-28B genotypes was detected in 85% of cases, with unfavorable genotypes less frequently — in 63% (p=0,028); the relapse rate is 27%. The level of HIV RNA viral load and the frequency of patients with secondary diseases was higher in patients with natural HCV/HIV infection with favorable interleukin-28B genotypes compared to other comparison groups (р<0,05).Conclusion. The course of chronic hepatitis C after therapy was more positive with favorable Il-28B genotypes. HIV infection was more severe in the absence of antiviral therapy for chronic hepatitis C.
Publisher
Baltic Medical Education Center
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,Immunology
Reference20 articles.
1. Wandeler G. Gsponer T., Bregenzer A. Hepatitis C virus infections in the swiss HIV cohort study: a rapidly evolving epidemic // Clin. Infect. Dis. 2012. Vol. 55, No. 10. P. 1408–1416. doi: 10.1093/cid/cis694.
2. Van der Helm J., Geskus R., Sabin C. Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997 // Gastroenterology. 2013. Vol. 144, No. 4. P. 751–760.
3. Karaulov A.V., Kalyuzhin O.V. Immunotherapy of infectious diseases: problems and prospects. Therapeutic archive, 2013, No. 11, рp. 100–108 (in Russ.). https://elibrary.ru/item.asp?id=21085880.
4. Ershov F.I., Narovlyansky A.N. Main results of research of the interferon system by 2011. Interferon-2011: collection of scientific articles, Moscow, 2012, рp. 14–34 (In Russ.).
5. Ge D., Fellay J., Thompson A.J. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance // Nature. 2009. Vol. 461, No. 7262. P. 399–401. doi: 10.1038/nature08309.